MX368142B - Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. - Google Patents

Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.

Info

Publication number
MX368142B
MX368142B MX2015015188A MX2015015188A MX368142B MX 368142 B MX368142 B MX 368142B MX 2015015188 A MX2015015188 A MX 2015015188A MX 2015015188 A MX2015015188 A MX 2015015188A MX 368142 B MX368142 B MX 368142B
Authority
MX
Mexico
Prior art keywords
ranibizumab
expression
preparation
purification method
novel cloning
Prior art date
Application number
MX2015015188A
Other languages
English (en)
Other versions
MX2015015188A (es
Inventor
Shandilya Harish
Gadgil Himanshu
Farkade Vivek
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2015015188A publication Critical patent/MX2015015188A/es
Publication of MX368142B publication Critical patent/MX368142B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la clonación, expresión y producción de Ranibizumab utilizando un abordaje novedoso para una proteína de mejor rendimiento y biológicamente activa.
MX2015015188A 2013-04-30 2014-04-28 Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. MX368142B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1570MU2013 2013-04-30
PCT/IN2014/000274 WO2014178078A2 (en) 2013-04-30 2014-04-28 Novel cloning, expression & purification method for the preparation of ranibizumab

Publications (2)

Publication Number Publication Date
MX2015015188A MX2015015188A (es) 2016-09-07
MX368142B true MX368142B (es) 2019-09-20

Family

ID=51844062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015188A MX368142B (es) 2013-04-30 2014-04-28 Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.

Country Status (7)

Country Link
US (1) US9914770B2 (es)
EP (1) EP2992021B1 (es)
CA (1) CA2911087A1 (es)
MX (1) MX368142B (es)
RU (1) RU2646098C2 (es)
WO (1) WO2014178078A2 (es)
ZA (1) ZA201508706B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3167065T1 (sl) * 2014-07-09 2020-09-30 Lupin Limited Dvojni cistronski bakterijski ekspresijski sistem
CN108026165A (zh) * 2015-08-17 2018-05-11 鲁平有限公司 用于抗体碎片的改进的复性方法
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
US11697672B2 (en) 2017-03-24 2023-07-11 Council Of Scientific & Industrial Research Process for the purification of recombinant antibody fragments
BR112019023795A2 (pt) * 2017-05-19 2020-07-28 Council Of Scientific & Industrial Research método para produzir ranibizumabe humanizado recombinante redobrado
CN119055798A (zh) 2017-12-19 2024-12-03 阿库斯股份有限公司 Aav介导的治疗性抗体到内耳的递送
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020037309A1 (en) * 2018-08-17 2020-02-20 Trican Biotechnology Co., Ltd. Anti-angiogenesis fusion protein and uses thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2021072182A1 (en) * 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
US20240092883A1 (en) * 2019-10-11 2024-03-21 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
CR20230228A (es) 2020-12-01 2023-07-18 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
CN115927472A (zh) * 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
US20250136673A1 (en) 2022-02-02 2025-05-01 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP2003503005A (ja) * 1998-07-28 2003-01-28 カリフォルニア インスティチュート オブ テクノロジー 機能的真核生物タンパク質の発現
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
EP1385872A4 (en) 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
DE10238846A1 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
BRPI0406470A (pt) * 2003-01-09 2005-12-06 Genentech Inc Método para a purificação de polipeptìdeo heterólogo e caldo ou homogeneizado de fermentação
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
WO2005103278A1 (ja) 2004-04-20 2005-11-03 Ajinomoto Co., Inc. タンパク質の製造法
EP2176291A1 (en) 2007-08-10 2010-04-21 Wacker Chemie AG Expression of full length igg and secretion into the culture medium of prokaryotic cells
JP2011514161A (ja) * 2008-02-29 2011-05-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 免疫グロブリン組成物およびその製造方法
US20090311750A1 (en) * 2008-06-13 2009-12-17 West James W Methods of converting fab sequences into single chain antibody sequences
US20100227905A1 (en) * 2009-03-03 2010-09-09 Alcon Research, Ltd. Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
EP2443150B1 (en) * 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CN102712673B (zh) 2010-01-22 2014-04-30 贝林格尔.英格海姆国际有限公司 用于纯化含fc的蛋白的色谱方法
WO2011104307A2 (en) * 2010-02-25 2011-09-01 Graffinity Pharmaceuticals Gmbh Ligands for antibody purification by affinity chromatography
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification

Also Published As

Publication number Publication date
US20160289314A1 (en) 2016-10-06
EP2992021A4 (en) 2017-01-11
MX2015015188A (es) 2016-09-07
CA2911087A1 (en) 2014-11-06
EP2992021B1 (en) 2020-07-22
ZA201508706B (en) 2017-09-27
EP2992021A2 (en) 2016-03-09
WO2014178078A2 (en) 2014-11-06
RU2015148746A (ru) 2017-06-05
US9914770B2 (en) 2018-03-13
RU2646098C2 (ru) 2018-03-01
WO2014178078A3 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
SG10201900948PA (en) Modified nucleotide linkers
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
SA515361251B1 (ar) طريقة لزيادة تكوين حمض بيرو-جلوتاميك من بروتين
IN2014CH00247A (es)
EA201590629A1 (ru) Новые лиганды rig-i и способы их получения
IN2015KN00323A (es)
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
PH12017502240A1 (en) Recombinant microorganism for improved production of alanine
PH12016501094A1 (en) Recombinant microorganism for improved production of fine chemicals
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
IN2014MU00455A (es)
IN2013MU03070A (es)
IN2013CH04906A (es)
MY184085A (en) Method of protein manufacture
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
MX349985B (es) Procedimiento de preparación de ésteres de fenilacetil aminoácido espirocíclicos con sustitución cis-alcoxi y derivados de 1h-pirrolidin-2,4-diona espirocicíclicos con sustitución cis-alcoxi.
MX368669B (es) Procedimiento para la preparación de 4-amino-1-((1s,4r,5s)-2-fluor o-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-o na.
HK1202555A1 (en) Process for the manufacture of cyclic undecapeptides
MX351329B (es) Proceso para elaborar derivados de magnolol.
EA201991474A1 (ru) Способы получения фитоина
MY173051A (en) Microorganism having producing ability of quinolinic acid and method for producing quinolinic acid using the microorganism
IN2013CH05865A (es)
IN2013MU02771A (es)
UA118585C2 (uk) Очистка епідаунорубіцину

Legal Events

Date Code Title Description
FG Grant or registration